Literature DB >> 12803973

Application of proteomics technology to the field of neurotrauma.

Nancy Denslow1, Mary Ellen Michel, Meredith D Temple, Chung Y Hsu, Kathryn Saatman, Ronald L Hayes.   

Abstract

Near-completion of the Human Genome Project has stimulated scientists to begin looking for the next step in unraveling normal and abnormal functions within biological systems. Consequently, there is new focus on the role of proteins in these processes. Proteomics is a burgeoning field that may provide a valuable approach to evaluate the post-traumatic central nervous system (CNS). Although we cannot provide a comprehensive assessment of all methods for protein analysis, this report summarizes some of the newer proteomic technologies that have propelled this field into the limelight and that are available to most researchers in neurotrauma. Three technical approaches (two-dimensional gel electrophoresis, direct analysis by mass spectrometry, including two-dimensional chromatography coupled to mass spectrometry and isotope coded affinity tags, and antibody technologies) are reviewed, and their advantages and disadvantages presented. A discussion of proteomic technology in the context of brain and spinal cord trauma follows, addressing current and future challenges. Proteomics will likely be very useful for developing diagnostic predictors after CNS injury and for mapping changes in proteins after injury in order to identify new therapeutic targets. Neurotrauma results in complex alterations to the biological systems within the nervous system, and these changes evolve over time. Exploration of the "new nervous system" that follows injury will require methods that can both fully assess and simplify this complexity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12803973     DOI: 10.1089/089771503765355487

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  8 in total

Review 1.  Blood-based diagnostics of traumatic brain injuries.

Authors:  Stefania Mondello; Uwe Muller; Andreas Jeromin; Jackson Streeter; Ronald L Hayes; Kevin K W Wang
Journal:  Expert Rev Mol Diagn       Date:  2011-01       Impact factor: 5.225

2.  Proteomic and phosphoproteomic analyses of the soluble fraction following acute spinal cord contusion in rats.

Authors:  Anshu Chen; Melanie L McEwen; Shixin Sun; Rangaswamyrao Ravikumar; Joe E Springer
Journal:  J Neurotrauma       Date:  2010-01       Impact factor: 5.269

Review 3.  Current status of fluid biomarkers in mild traumatic brain injury.

Authors:  Jacqueline R Kulbe; James W Geddes
Journal:  Exp Neurol       Date:  2015-05-14       Impact factor: 5.330

Review 4.  Post-genomics nanotechnology is gaining momentum: nanoproteomics and applications in life sciences.

Authors:  Firas H Kobeissy; Basri Gulbakan; Ali Alawieh; Pierre Karam; Zhiqun Zhang; Joy D Guingab-Cagmat; Stefania Mondello; Weihong Tan; John Anagli; Kevin Wang
Journal:  OMICS       Date:  2014-01-10

5.  Traumatic brain injury stimulates hippocampal catechol-O-methyl transferase expression in microglia.

Authors:  John B Redell; Pramod K Dash
Journal:  Neurosci Lett       Date:  2006-12-15       Impact factor: 3.046

6.  Protein biomarkers for traumatic and ischemic brain injury: from bench to bedside.

Authors:  Zhiqun Zhang; Stefania Mondello; Firas Kobeissy; Richard Rubenstein; Jackson Streeter; Ronald L Hayes; Kevin K W Wang
Journal:  Transl Stroke Res       Date:  2011-12-07       Impact factor: 6.829

7.  Involvement of acidic fibroblast growth factor in spinal cord injury repair processes revealed by a proteomics approach.

Authors:  Ming-Chu Tsai; Li-Fen Shen; Huai-Sheng Kuo; Henrich Cheng; Kin-Fu Chak
Journal:  Mol Cell Proteomics       Date:  2008-05-14       Impact factor: 5.911

Review 8.  Systematic review of clinical research on biomarkers for pediatric traumatic brain injury.

Authors:  Linda Papa; Michelle M Ramia; Jared M Kelly; Stephen S Burks; Artur Pawlowicz; Rachel P Berger
Journal:  J Neurotrauma       Date:  2013-02-15       Impact factor: 5.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.